Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VBC103 in Advanced Malignant Solid Tumors
NCT07299747Phase 2Recruiting
- Sponsor
- VelaVigo
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of AVZO-103 in solid tumor, sponsored by VelaVigo. Started Dec 2025; status: recruiting.
02
Drugs
AVZO-103
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07299747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07299747.